CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103913
Első szerző:Katkó Mónika (biológus)
Cím:The effect of iatrogenic hypothyroidism on lipoprotein subfractions and serum paraoxonase activity in patients with differentiated thyroid cancer / Katkó M., Gazdag A., Harangi M., Szentpéteri A., Galgóczi E., Erdei A., Berta E., Bodor M., Bhattoa H. P., Nagy E. V.
Dátum:2022
ISSN:0021-9150
Megjegyzések:Background and Aims : The development of atherogenic lipid profile has a major role in hypothyroidism induced accelerated atherosclerosis. In a group of patients with differentiated thyroid cancer (DTC) subclinical hyperthyroidism is maintained after thyroidectomy, interrupted annually with short-term overt hypothyroidism for diagnostic purposes. The effects of short-term overt hypothyroidism on lipid parameters, lipoprotein subfractions and paraoxonase-1 (PON1) activity were studied in these patients. Methods: Twenty-one patients who underwent total thyroidectomy and ablative radioiodine therapy for DTC were enrolled in the study. Blood samples were collected during continuous TSH-suppressive levothyroxine (L-T4) therapy and after four weeks of L-T4 withdrawal. Thyroid hormones, lipid parameters and PON1 paraoxonase and arylesterase activity were measured, analysis of lipoprotein subfractions was performed by Lipoprint system. Results: Compared to values measured during continuous L-T4 therapy, total cholesterol, HDL-C, LDL-C, ApoA1, ApoB levels were significantly elevated during iatrogenic hypothyroidism. Differences in the subfraction pattern of lipoproteins were also observed: in hypothyroidism, the mean LDL size decreased (26.9?0.4 nm vs 27.1?0.4 nm, p<0.01) and the proportion of small and medium-sized HDL subfractions decreased (29.5?9.9% vs 33.8?8.6%, p<0.001, and 43.8?4.6% vs 46.1?5.1%, p=0.005, respectively), while the proportion of large HDL subfractions increased (26.8?9.8% vs 20.0?6.9%, p<0.0001). The PON1 paraoxonase and arylesterase activities were increased during L-T4 withdrawal (113?67 U/L vs 106?67 U/L, p=0.005; and 159?44 U/L vs 134?21 U/L, p<0.01; respectively). Conclusions: In short-term overt hypothyroidism both atherogenic and anti-atherogenic changes were found: the shift toward lower density LDL subfractions is atherogenic, while the increased proportion of larger HDL subfractions and increased paraoxonase activity are anti-atherogenic.
Tárgyszavak:Orvostudományok Egészségtudományok idézhető absztrakt
folyóiratcikk
iatrogenic hypothyroidism
differentiated thyroid cancer
paraoxonase-1
lipoprotein subfraction
lipid metabolism
Megjelenés:Atherosclerosis. - 355 (2022), p. e163. -
További szerzők:Gazdag Annamária (1979-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Szentpéteri Anita (1988-) (biológus) Galgóczi Erika (1986-) (biológus) Erdei Annamária (1976-) (belgyógyász) Berta Eszter (1980-) (belgyógyász) Bodor Miklós (1969-) (belgyógyász, endokrinológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Nagy Endre V. (1957-) (belgyógyász, endokrinológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM103904
Első szerző:Lőrincz Hajnalka (biológus)
Cím:Plasminogen activator inhibitor-1 level associated with the components of metabolic syndrome in a 4G/5G polymorphism dependent manner / Lőrincz H., Galgóczy E., Katkó M., Ratku B., Ötvös T., Harangi M., Paragh G., Szabó Z., Somodi S.
Dátum:2022
ISSN:0021-9150
Megjegyzések:Background and Aims : The elevated level of plasminogen activator inhibitor- 1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. A common 4G/5G single guanine insertion/deletion polymorphism in the promoter region of the PAI-1 gene is of functional importance in regulating PAI-1 expression. We aimed to study the potential different correlations of carbohydrate and lipid parameters and plasma PAI-1 levels in the 4G and 5G carriers in obese and lean subjects. Methods: Ninety-three morbid obese and thirty-two lean non-diabetic participants were enrolled. PAI-1 4G/5G polymorphism was determined with allele-specific PCR. Plasma PAI-1 levels were measured by ELISA. Results: The genotype distribution of PAI-1 4G/5G polymorphism was not significantly differed in obese patients (4G/4G 27.9%; 4G/5G 45.2% and 5G/ 5G 26.9%) compared to controls (4G/4G 31.3%; 4G/5G 46.9% and 5G/5G 21.9%, p?0.8). Slightly higher PAI-1 levels were found in 4G carriers (4G/ 4G+4G/5G) in obese and control group (p?0.07 and p?0.02, respectively). In all subjects with 4G/5G genotype, plasma PAI-1 correlated negatively with high-density lipoprotein-cholesterol (HDL-C) (p?0.02) and apolipoprotein AI (apoAI) levels (p<0.001). In 5G/5G participants, PAI-1 also correlated negatively with HDL-C (p?0.025) and apoAI (p?0.007) concentrations, moreover positively with triglyceride (p?0.02), fasting glucose (p?0.002) and haemoglobin A1c (p?0.027). These correlations are lacking in 4G/4G participants. Conclusions: The observed correlations between PAI-1 levels and the components of metabolic syndrome suggest a closer link between PAI-1 and lipid and carbohydrate metabolism in subjects with 5G/5G genotype. This presentation was supported by the Bridging Fund (Faculty of Medicine, University of Debrecen) and PD124126 project.
Tárgyszavak:Orvostudományok Egészségtudományok idézhető absztrakt
folyóiratcikk
atherosclerosis
Plasminogen activator inhibitor-1
promoter polymorphism
obesity
lipid metabolism
lipoprotein
Megjelenés:Atherosclerosis. - 355 (2022), p. e248. -
További szerzők:Galgóczi Erika (1986-) (biológus) Katkó Mónika (1980-) (biológus) Ratku Balázs (1985-) (mentőtiszt) Ötvös Tamás (1980-) (orvos) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Somodi Sándor (1977-) (belgyógyász)
Pályázati támogatás:PD124126
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1